{
  "docId": "019de06f-55b4-734a-a2e3-c1019ed629b5",
  "docSlug": "42b17c6fff3e2006bf9fc5d84bd6edcc",
  "documentTitle": "Pershing Square | Activist Presentation Deck | 120 slides",
  "authorId": "pershing-square",
  "authorName": "Pershing Square Capital Management, L.P.",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2955465,
  "pageNumber": 120,
  "pageCount": 120,
  "prevPage": 119,
  "nextPage": null,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 120,
  "notes": "The slide uses callouts to contrast Allergan's low performance-based pay and low TSR against Valeant and the peer group average.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de06f-55b4-734a-a2e3-c1019ed629b5/120",
  "deckHref": "/decks/019de06f-55b4-734a-a2e3-c1019ed629b5",
  "deckJsonHref": "/decks/019de06f-55b4-734a-a2e3-c1019ed629b5.json",
  "deckAnchorHref": "/decks/019de06f-55b4-734a-a2e3-c1019ed629b5#slide-120",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.18,
        "x": 0.75,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Significant misalignment between pay and shareholder returns, relative to peers",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f0caf5d-12e2-403e-86e1-3d8334a0e6a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.18,
        "x": 0.42,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Only 13% of total compensation tied to performance",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1082f04-ca95-46cf-8882-1f2b5388189b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.18,
        "x": 0.56,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Contrast to Valeant management – Performance-based incentive pay is 68% of total compensation",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c42f45c2-c5ff-4244-ac1b-cc6bc3569588",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.12,
        "x": 0.85,
        "y": 0.88
      },
      "kind": "callout",
      "text": "Contrast to Valeant management – shareholder alignment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e410cbfa-1b67-4fe2-985c-712172874fa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: ISS reports. Note: Based on Allergan's proxy peers.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f07c36e1-6879-434c-9aa9-e4637f7a2d4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "table",
      "text": "Table of CEO compensation data for Biotech, Medical Devices, and Pharmaceutical companies.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "975aa983-a43d-47dc-93a2-276d9d093ba1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Allergan's Compensation Policy Further Reduces the Credibility of the Revised Long-Term Plan",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb2df1f0-1bc5-4a53-822d-290eed6c1fa1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "c726ec77-3136-482e-844e-791fecfb5dbc",
      "evidence": "Table/data with callouts for contrast to Valeant management",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "8950ef30-5e60-4325-ab74-7d808b7c7485",
      "evidence": "Direct comparison of Allergan against peer group and Valeant to highlight performance misalignment.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}